Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T10096L |
Voruciclib
|
CDK | Cell Cycle/Checkpoint |
Voruciclib 是一种具有口服活性和选择性 CDK 抑制剂,Ki 为 0.626 nM-9.1 nM。它在多种弥漫性大 B 细胞淋巴瘤模型中抑制 MCL-1 的表达。它有效阻断 MCL-1 的转录调节子 CDK9。 | |||
T10096L2 |
(2S,3R)-Voruciclib hydrochloride
(2S,3R)-Voruciclib hydrochloride (1253731-24-6 free base) |
Others | Others |
(2S,3R)-Voruciclib hydrochloride is the (2S,3R)-enantiomer of Voruciclib. It is an orally active CDK inhibitor. | |||
T13309 | Voruciclib hydrochloride | CDK | Cell Cycle/Checkpoint |
Voruciclib hydrochloride is an orally active and selective inhibitor of CDK (Ki: 0.626 nM-9.1 nM). | |||
T10096 |
(2S,3R)-Voruciclib
|
CDK | Cell Cycle/Checkpoint |
(2S,3R)-Voruciclib is the (2S,3R)-enantiomer of Voruciclib. It is an orally active CDK inhibitor. | |||
T63465 | (2S,3R)-Voruciclib hydrochloride | ||
(2S,3R)-Voruciclib hydrochloride 是一种 Voruciclib hydrochloride 的异构体。其中 Voruciclib 是口服具有活力的 CDK 抑制剂。 | |||
T78048 |
rel-(2S,3R)-Voruciclib hydrochloride
|
CDK | Cell Cycle/Checkpoint |
rel-(2S,3R)-Voruciclib hydrochloride为Voruciclib hydrochloride的一种异构体,该化合物为口服活性的CDK(cyclin-dependent kinases)抑制剂。 |